首页 › 克罗恩病 › 纽约州

纽约州的克罗恩病临床试验

纽约州有 36 项针对克罗恩病的研究正在招募参与者。

纽约州的城市

官方研究文本（英文）

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

New York Gastroenterology Associates ( Site 0253), New York

招募中3 期

所有年龄段 · 所有性别 · 更新于 2026年10月2日 · NCT06651281

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Northwell Health Physician Partners Center for Advanced IBD Care ( Site 5017), Great Neck
NYU Langone Health - Inflammatory Bowel Disease Center (IBD) ( Site 5078), New York
Weill Cornell Medical College, New-York Presbyterian Hospital ( Site 5079), New York
以及另外 2 项

招募中3 期

16 至 80 岁 · 所有性别 · 更新于 2026年10月2日 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

New York Gastroenterology Associates - Upper East Side /ID# 281767, New York

招募中2 期

18 至 75 岁 · 所有性别 · 更新于 2026年10月2日 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

Westchester Putnam Gastroenterology PC, Carmel
Five Towns Gastroenterology, Cedarhurst
IMIDeology, Elmhurst
以及另外 5 项

招募中4 期

18 至 80 岁 · 所有性别 · 更新于 2026年9月30日 · NCT06581328

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
Icahn School of Medicine at Mount Sinai, New York

招募中3 期

2 至 17 岁 · 所有性别 · 更新于 2026年9月25日 · NCT05923073

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Nyu Langone Long Island Clinical Research Associates - Lake Success /ID# 265566, Lake Success
Northwell Health-Lenox Hill Hospital /ID# 265527, New York
Care Access - Yonkers /ID# 266781, Yonkers

招募中2 期

18 至 75 岁 · 所有性别 · 更新于 2026年9月25日 · NCT06548542

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Westchester Putnam Gastroenterology, Carmel
New York Gastroenterology Associates, New York

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07499232

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Westchester Putnam Gastroenterology, Carmel
Inflammatory Bowel Disease Center at NYU Langone, New York
Weill Cornell Medical College, New York
以及另外 2 项

招募中2/3 期

18 岁及以上 · 所有性别 · 更新于 2026年9月25日 · NCT07196722

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York
Rochester Clinical Research, Inc, Rochester

招募中2 期

18 至 75 岁 · 所有性别 · 更新于 2026年9月25日 · NCT06233461

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

New York Gastroenterology Associates, New York
Care Access - Yonkers, Yonkers

招募中3 期

18 至 70 岁 · 所有性别 · 更新于 2026年9月24日 · NCT06937099

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NYU Langone Hospital - Long Island, Mineola
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
以及另外 1 项

招募中1 期

18 岁及以上 · 所有性别 · 更新于 2026年9月23日 · NCT03816345

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

MedTraits NY-Site Number: 8400045, Maspeth
Manhattan Clinical Research, LLC-Site Number: 8400069, New York
NYU Langone Health-Site Number: 8400091, New York
以及另外 4 项

招募中3 期

16 至 80 岁 · 所有性别 · 更新于 2026年9月23日 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

MedTraits NY-Site Number: 8400045, Maspeth
NYU Langone Health-Site Number: 8400091, New York
Weill Cornell Medicine - NewYork-Presbyterian Hospital-Site Number: 8400040, New York
以及另外 1 项

招募中3 期

16 至 80 岁 · 所有性别 · 更新于 2026年9月23日 · NCT07184944

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Icahn School of Medicine at Mount Sinai /ID# 254880, New York

招募中3 期

2 至 17 岁 · 所有性别 · 更新于 2026年9月23日 · NCT05995353

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Icahn School of Medicine at Mount Sinai, New York

招募中3 期

2 至 19 岁 · 所有性别 · 更新于 2026年9月22日 · NCT04844606

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

NYU Langone Health, New York

招募中4 期

18 至 70 岁 · 所有性别 · 更新于 2026年9月9日 · NCT06045754

Standardized Microbiota Transplant Therapy in Crohn's Disease

NYU Langone Health, New York

招募中2 期

18 至 89 岁 · 所有性别 · 更新于 2026年9月8日 · NCT06631586

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

New York Gastroenterology Associates, New York

招募中3 期

18 岁及以上 · 所有性别 · 更新于 2026年8月28日 · NCT07577843

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
Icahn School of Medicine at Mount Sinai, New York
Columbia University Medical Center/New York Presbyterian, New York

招募中3 期

2 至 17 岁 · 所有性别 · 更新于 2026年8月24日 · NCT05509777